| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB |
NCT05180032: Treatment With Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI |
|
|
| Recruiting | 4 | 39 | US | Romoszumab, Evenity, Denosumab, Prolia, Placebo | James J. Peters Veterans Affairs Medical Center, Kessler Institute for Rehabilitation | Osteoporosis, Spinal Cord Injuries | 03/25 | 03/27 | | |
NCT05101018: Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI |
|
|
| Active, not recruiting | 4 | 40 | US | Romosozumab, Evenity, Denosumab, Prolia | James J. Peters Veterans Affairs Medical Center, Kessler Institute for Rehabilitation | Osteoporosis, Spinal Cord Injuries | 11/25 | 11/27 | | |
NCT06079476: A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. |
|
|
| Recruiting | 4 | 100 | RoW | Romosozumab | Amgen | Postmenopausal Osteoporosis | 11/25 | 11/25 | | |
NCT05067335: A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis |
|
|
| Completed | 3 | 564 | RoW | Romosozumab, Placebo | UCB Biopharma SRL | Osteoporosis | 11/23 | 11/23 | | |
NCT04779216: Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa |
|
|
| Active, not recruiting | 3 | 30 | US | Romosozumab Prefilled Syringe, Placebo, Alendronate 70Mg Tab | Karen Klahr Miller, MD, Amgen | Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders | 09/24 | 09/25 | | |
NCT05972551: Study to Evaluate Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta |
|
|
| Recruiting | 3 | 106 | Europe, Canada, Japan, US, RoW | Romosozumab, EVENITY®, Bisphosphonate | Amgen | Osteogenesis Imperfecta | 02/27 | 05/27 | | |
NCT04232657: Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI |
|
|
| Active, not recruiting | 2 | 36 | US | Romosozumab, Evenity, Denosumab, Prolia, Placebo, Normal Saline (NS) injection | VA Office of Research and Development, Kessler Institute for Rehabilitation | Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI | 02/26 | 03/27 | | |
| Completed | 2 | 12 | US | Romosozumab, Evenity, Alendronate, Fosamax | Northwestern University, Amgen | Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries, Chronic Spinal Paralysis | 06/24 | 06/24 | | |
NCT04800367: Romosozumab/Denosumab Study for Premenopausal IOP |
|
|
| Recruiting | 2 | 30 | US | Romosozumab Prefilled Syringe [Evenity], Evenity, Denosumab 60 MG/ML Prefilled Syringe [Prolia], Prolia | Columbia University, Amgen | Premenopausal Idiopathic Osteoporosis | 03/25 | 03/26 | | |
| Completed | 1 | 25 | Europe, US, RoW | Romosozumab, Calcium, Vitamin D | Amgen | Osteogenesis Imperfecta | 03/23 | 03/23 | | |